Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022
by from Morbidity and Mortality Weekly Report (MMWR) on (#5WFPD)
This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.